This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cramer's 'Mad Money' Recap: Riches in Cheap Threads

Cramer expects BioCryst's stock to jump whenever avian flu gets mentioned in the media, he said. At that point, you should sell it. If in six months nothing has happened and no one is talking about avian flu, you should sell it then, too, he said.

Also, don't pay up for the stock, he advised. Try to buy it at least within 50 cents or so of where the stock closed the regular trading session Monday at $12.98, said Cramer.

Tanker Play

Cramer is changing his tune on oil tanker shipping company General Maritime (GMR). Cramer has been bearish on GMR "for 20 points down," he said. But, rates for midsized oil tankers are up 20% to 30% so far in October in the wake of hurricanes Katrina and Rita, and GRM is the pure play on midsized oil tankers, with the world's second largest midsized tanker fleet, he said.

Cramer also mentioned Teekay Shipping (TK), which has the world's largest fleet of midsized oil tankers. But Teekay also owns one large-class oil tanker, and rates for the largest class of tankers have declined 50% vs. last year's average and are not recovering strongly, said Cramer.

"General Maritime's rates are recovering," said Cramer. "The rest of the tanker business is sitting dead in the water ... You go with GMR."

Word, Docs

Allscripts Healthcare Solutions' (MDRX - Get Report) CEO Glen Tullman spoke with Cramer on the phone. Cramer asked Tullman how close doctors are to having fully computerized offices.

Tullman said the trend is just beginning. "It's turned for the big physician groups, and it's starting to turn in the mid-market," he said.

Cramer asked why Allscripts' solutions were better than competitors' offerings such those from Quality Systems (QSII), "another company I like a lot," said Cramer.

Tullman said Allscripts' product is easier to install and use and that Allscripts has a built-in advantage in the high-end market because of its relationship with practice-management software provider, IDX Systems (IDXC).
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMZN $659.59 0.00%
BCRX $3.26 0.00%
CHK $6.87 0.00%
FPL $13.14 0.00%
GME $32.80 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs